id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-301087-9vl5pqi7	Teh, Benjamin W.	Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital	2014-12-10		.txt	text/plain	2634	147	41	The epidemiology, risk factors and outcomes of viral respiratory tract infections (vRTI) are not well described in patients with multiple myeloma managed with novel agents, the current standard of care. Whilst the epidemiology, clinical outcomes and risk factors associated with viral RTI (vRTI) are well known in the haematopoietic stem cell transplant (HSCT) setting and supported by appropriate management guidelines, these characteristics have not been reported in myeloma patients managed with novel agents [5, 6] . Patients were identified retrospectively from chemotherapy drug dispensing and microbiology databases using the following criteria: a confirmed diagnosis of multiple myeloma, received active therapy with IMiD or PI and tested positive for respiratory viral (RV) infection by nucleic acid amplification testing (NAT) at Peter MacCallum Cancer Centre (PMCC) from January 2009 to December 2012. Clinical records of eligible patients were reviewed using a standardized tool to capture the following: patient demographics, myeloma therapy, seasonality of infection, radiological changes, clinical features and outcomes (length of stay (LOS)), requirement for intensive care (ICU) management and all-cause mortality at 30 days).	./cache/cord-301087-9vl5pqi7.txt	./txt/cord-301087-9vl5pqi7.txt